Cargando…

Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer

Thyroid cancer is the most common endocrine malignancy, affecting nearly 600,000 new patients worldwide. Treatment with the BRAF inhibitor sorafenib partially prolongs progression-free survival in thyroid cancer patients, but fails to improve overall survival. This study examines enhancing sorafenib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mortensen, Anja Charlotte Lundgren, Berglund, Hanna, Hariri, Mehran, Papalanis, Eleftherios, Malmberg, Christer, Spiegelberg, Diana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558458/ https://www.ncbi.nlm.nih.gov/pubmed/37803074 http://dx.doi.org/10.1038/s41598-023-43486-z

Ejemplares similares

Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib
por: Mortensen, Anja Charlotte Lundgren, et al.
Publicado: (2020)

The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach
por: Spiegelberg, Diana, et al.
Publicado: (2020)

The HSP90 inhibitor onalespib potentiates (177)Lu-DOTATATE therapy in neuroendocrine tumor cells
por: Lundsten, Sara, et al.
Publicado: (2019)

Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib
por: Courtin, Aurelie, et al.
Publicado: (2016)

The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells
por: Spiegelberg, Diana, et al.
Publicado: (2015)

The radiosensitizer Onalespib increases complete remission in (177)Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts
por: Lundsten, Sara, et al.
Publicado: (2020)

Inhibitors of HSP90 in melanoma
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

Enhanced Therapeutic Effects of (177)Lu-DOTA-M5A in Combination with Heat Shock Protein 90 Inhibitor Onalespib in Colorectal Cancer Xenografts
por: Mohajershojai, Tabassom, et al.
Publicado: (2023)

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
por: Lu, Ziwen, et al.
Publicado: (2022)

Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model
por: Spiegelberg, Diana, et al.
Publicado: (2015)

Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia
por: Khajapeer, Kalubai Vari, et al.
Publicado: (2015)

Hsp90 Inhibitor Can Inhibit UV-Carcinogenesis
por: Katiyar, Santosh K.
Publicado: (2015)

Circumventing HSP90 inhibitors via apoptosis block
por: Fennell, Dean A., et al.
Publicado: (2015)

Identification and characterization of the antiplasmodial activity of Hsp90 inhibitors
por: Murillo-Solano, Claribel, et al.
Publicado: (2017)

Inhibition of the NLRP3 inflammasome by HSP90 inhibitors
por: Nizami, Sohaib, et al.
Publicado: (2020)

The Role of HSP90 Inhibitors in the Treatment of Cardiovascular Diseases
por: Qi, Shiyu, et al.
Publicado: (2022)

Upregulation of TGF-β-induced HSP27 by HSP90 inhibitors in osteoblasts
por: Kuroyanagi, Gen, et al.
Publicado: (2022)

Hsp90 Inhibitors Prevent HSV-1 Replication by Directly Targeting UL42-Hsp90 Complex
por: Qin, Shurong, et al.
Publicado: (2022)

Effects of Sorafenib, a Tyrosin Kinase Inhibitor, on Adrenocortical Cancer
por: Cerquetti, Lidia, et al.
Publicado: (2021)

The broad stroke of Hsp90 inhibitors: painting over the RAF inhibitor paradox
por: Vido, Michael, et al.
Publicado: (2015)

HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
por: Kijima, Toshiki, et al.
Publicado: (2018)

Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors
por: Woodford, Mark R., et al.
Publicado: (2016)

Hsp90 inhibitor induces autophagy and apoptosis in osteosarcoma cells
por: MORI, MASAKI, et al.
Publicado: (2014)

Molecular Dynamics Simulations of Hsp90 with an Eye to Inhibitor Design
por: Moroni, Elisabetta, et al.
Publicado: (2012)

Identification of HSP90 inhibitors as a novel class of senolytics
por: Fuhrmann-Stroissnigg, Heike, et al.
Publicado: (2017)

Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas
por: Pecori Giraldi, Francesca, et al.
Publicado: (2023)

The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model
por: Spiegelberg, Diana, et al.
Publicado: (2020)

Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors
por: Gillis, Joanna L., et al.
Publicado: (2013)

Cancer cell responses to Hsp70 inhibitor JG-98: Comparison with Hsp90 inhibitors and finding synergistic drug combinations
por: Yaglom, Julia A., et al.
Publicado: (2018)

The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1
por: Usmani, Saad Z, et al.
Publicado: (2010)

Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors
por: Rodrigues Moita, Ana J., et al.
Publicado: (2020)

Identification of the Plant Compound Geraniin as a Novel Hsp90 Inhibitor
por: Vassallo, Antonio, et al.
Publicado: (2013)

The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells
por: Gomez-Casal, Roberto, et al.
Publicado: (2015)

High-Throughput Screen of Natural Product Libraries for Hsp90 Inhibitors
por: Davenport, Jason, et al.
Publicado: (2014)

Essential oil from Cymbopogon flexuosus as the potential inhibitor for HSP90
por: Gaonkar, Roopa, et al.
Publicado: (2018)

Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Discovery of small molecule inhibitors of Leishmania braziliensis Hsp90 chaperone
por: Batista, Fernanda A. H., et al.
Publicado: (2020)

Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma
por: Marrugal, Ángela, et al.
Publicado: (2021)

Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications
por: Ardestani, Mina, et al.
Publicado: (2022)

HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)
por: Li, Zi-Nan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lgnva0ab3vg2ecvjovfip43h8n